Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027

Phase 1/2 trial of CR-003 (SKB105), an ITGB6-targeted ADC, ongoing in China; initial data expected in Q1 2027

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.